Proactive Investors - Run By Investors For Investors

e-Therapeutics refocused and well-funded

The company underwent something of a transition in the first six months of the year, reorganising its board and shifting its focus
test tubes in a rack
e-therapeutics wants to focus on a smaller selection of projects

Drug discovery firm e-Therapeutics PLC (LON:ETX) said it has emerged from the first half with “increased enthusiasm and determination” after undergoing something of a transition in the first six months of 2016.

Its former chief executive and founder Malcolm Young, as well as development director Steve Self, stepped down as the company moved its focus more to the discovery side of it operations.

The half saw e-Therapeutics complete the acquisition of internet search engine technology developer Searchbolt for an initial £2.32mln.

The firm also made progress on its two lead compounds, ETS6103, a compound aimed at treating major depressive disease, and ETS2101, a potential cancer treatment.

e-Therapeutics said it will look to out-license both of these programmes at the appropriate time.

“This has been a busy six months which has seen fundamental changes to the business and its strategy,” said chairman Iain Ross.

"We have a world-beating discovery engine with potent and significant programmes in our pipeline. We have a refocused and committed team, a targeted commercial partnership strategy and the support of a strong balance sheet.”

e-Therapeutics had 17 discovery projects at different levels of progress at the end of the period, and undertook a scientific and business review back in July to prioritise its focus.

 “We were just trying to do too many things. What we’ve now done is focus down to the projects which we think have the most likelihood of being partnered by big pharma,” added Ross.

As a result of the large number of programmes in progress during the first half, discovery project spend rose to £2.5mln (1H 2015: £0.9mln).

The company has now pinpointed five projects it intends to focus on, as well as five earlier-stage projects which will act like understudies.

Ross told investors: “Our real focus is the discovery engine, those five projects in medicinal chemistry are where the real value of the company is.”

In the six months to the end of July, e-Therapeutics reported a total loss of £7.9mln.

The company finished the period with £19.9mln in cash having burned through £4.9mln, which it is confident will be enough to support the business into 2019.

The company said it is on track to find a replacement for Malcolm Young before the year is out and Ross highlighted what it is the board is looking for.

“I would like to see somebody who is scientifically qualified but who has also worked on the business side of things.”

Shares closed down 15% to 9p.

--Updates for chairman comment and share price--

View full ETX profile View Profile

e-Therapeutics plc Timeline

CN Video
March 28 2018

Related Articles

November 19 2018
“It’s a blended model of highly cash generative assets and top line growth”
Callitas CEO James Thompson
July 20 2018
CannaStrips will generate near-term revenue, while the company’s blue-sky pharmaceutical assets and orphan drug are solid, long-term plays
Under former chief executive Peter George and his successor Shaun Chilton, Clinigen has been transformed via a series of well-judged, quickly integrated and cash generative acquisitions

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use